Extra-intestinal malignancies in inflammatory bowel disease: results of the 3rd ECCO Pathogenesis Scientific Workshop (III).

scientific article published on 27 May 2013

Extra-intestinal malignancies in inflammatory bowel disease: results of the 3rd ECCO Pathogenesis Scientific Workshop (III). is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/J.CROHNS.2013.04.006
P698PubMed publication ID23721759
P5875ResearchGate publication ID236976381

P50authorLaurent Peyrin-BirouletQ30248039
Fernando MagroQ37840060
Laurent BeaugerieQ72537856
P2093author name stringKonstantinos H Katsanos
Harry Sokol
Peter D Higgins
Anthony Lopez
Antonia Costa
Elena Toader
Joel C Joyce
Teresa Mas de Xaxars
Xavier Aldeger
P2860cites workMeta-analysis of systemic lupus erythematosus and the risk of cervical neoplasiaQ37798607
P433issue1
P921main subjectinflammationQ101991
inflammatory bowel diseasesQ917447
workshopQ27556165
P304page(s)31-44
P577publication date2013-05-27
P1433published inJournal of Crohn's and ColitisQ15817379
P1476titleExtra-intestinal malignancies in inflammatory bowel disease: results of the 3rd ECCO Pathogenesis Scientific Workshop (III).
P478volume8

Reverse relations

cites work (P2860)
Q40513902A population-based study examining the risk of malignancy in patients diagnosed with inflammatory bowel disease.
Q39029698ACG Clinical Guideline: Preventive Care in Inflammatory Bowel Disease
Q26745782Advances in the development of new biologics in inflammatory bowel disease
Q39221586Anal Neoplasia in Inflammatory Bowel Disease: Classification Proposal, Epidemiology, Carcinogenesis, and Risk Management Perspectives
Q38582914Anti-TNF agents in patients with inflammatory bowel disease and malignant melanoma--challenges in management
Q37354812Anti-TNFα therapy for chronic inflammatory disease in kidney transplant recipients: Clinical outcomes
Q88775678Anti-Tumor Necrosis Factor Therapy in Intestinal Behçet's Disease
Q35534959Cancer and immunomodulators in inflammatory bowel diseases
Q37540172Care of inflammatory bowel disease patients in remission
Q26752869Crohn's disease and skin
Q28085134Differential diagnosis in inflammatory bowel disease colitis: state of the art and future perspectives
Q92759074Elderly patients with inflammatory bowel disease: Updated review of the therapeutic landscape
Q41293583Epstein-Barr virus in inflammatory bowel disease: the spectrum of intestinal lymphoproliferative disorders
Q41990807European Crohn's and Colitis Organisation Topical Review on Treatment Withdrawal ('Exit Strategies') in Inflammatory Bowel Disease.
Q50079201Evidence-based clinical practice guidelines for inflammatory bowel disease.
Q28236322Golimumab for the treatment of ulcerative colitis
Q33621700Healthcare maintenance in elderly patients with inflammatory bowel disease
Q54299159Hodgkin's Lymphoma in Crohn's Disease Treated with Infliximab.
Q28076561How I treat my inflammatory bowel disease-patients with thiopurines?
Q38743666Immunomodulators for the treatment of Crohn's disease in adults: optimal use and prospects for future drug treatments
Q50451653Incidence, management, and course of cancer in patients with inflammatory bowel disease.
Q39773210Inflammatory bowel disease, cancer and medication: Cancer risk in the Dutch population-based IBDSL cohort
Q26823569Interventions and targets aimed at improving quality in inflammatory bowel disease ambulatory care
Q44262408Ionizing radiation exposure in patients with inflammatory bowel disease: are we overexposing our patients?
Q59357120Lymphoproliferative Disorders in Inflammatory Bowel Disease Patients: Is It the Drugs or the Disease
Q38814448Malignancies in Patients with Inflammatory Bowel Disease: Results from 20 Years of Follow-up in the IBSEN Study
Q40303601Metastatic Epstein-Barr Virus-Positive Lymphoepithelioma-Like Cholangiocarcinoma in a Young Man With Ulcerative Colitis
Q38585910Monitoring for Extra-Intestinal Cancers in IBD.
Q64259900Multidisciplinary, evidence-based consensus guidelines for human papillomavirus (HPV) vaccination in high-risk populations, Spain, 2016
Q38550831Oxidative Stress and DNA Damage: Implications in Inflammatory Bowel Disease.
Q39375417PDE4 Inhibition and Inflammatory Bowel Disease: A Novel Therapeutic Avenue
Q57167308Positioning of old and new biologicals and small molecules in the treatment of inflammatory bowel diseases
Q49566489Postoperative therapy with infliximab for Crohn's disease: a 2-year prospective randomized multicenter study in Japan
Q38835478Practical Approaches to "Top-Down" Therapies for Crohn's Disease
Q35193565Review article: why, when and how to de-escalate therapy in inflammatory bowel diseases.
Q41726526Risk of Lymphoma, Colorectal and Skin Cancer in Patients with IBD Treated with Immunomodulators and Biologics: A Quebec Claims Database Study
Q37439950Risk of cancer, with special reference to extra-intestinal malignancies, in patients with inflammatory bowel disease
Q48249329Safe use of infliximab for the treatment of severe perianal Crohn's disease after diagnosis and treatment of lymphoma.
Q38611360Safety of Anti-TNF Therapies in Immune-Mediated Inflammatory Diseases: Focus on Infections and Malignancy.
Q41150136Seroprevalence of Epstein-Barr Virus, Cytomegalovirus, and Polyomaviruses in Children with Inflammatory Bowel Disease.
Q38180195Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor-α therapy in inflammatory bowel disease.
Q38527999Systematic review: factors associated with relapse of inflammatory bowel disease after discontinuation of anti-TNF therapy.
Q89706131The Complex Interplay Between Inflammatory Bowel Disease and Malignancy
Q91856952The Role of Vitamin D in Inflammatory Bowel Disease: Mechanism to Management
Q60017517The current state of the art for biological therapies and new small molecules in inflammatory bowel disease
Q38357796The epidemiology of inflammatory bowel disease
Q38237701The role and advances of immunomodulator therapy for inflammatory bowel disease
Q39985219The safety of vedolizumab for ulcerative colitis and Crohn's disease
Q58111244Trends of Medication Usage and Associated Outcomes for Taiwanese Patients with Inflammatory Bowel Disease from 2001 to 2015
Q38977012Understanding the complications of anti-tumor necrosis factor therapy in East Asian patients with inflammatory bowel disease
Q26750190Use of biologics and chemotherapy in patients with inflammatory bowel diseases and cancer
Q33621267Use of thiopurines in inflammatory bowel disease: Safety issues
Q90444106Usefulness of Thiopurine Monotherapy for Crohn's Disease in the Era of Biologics: A Long-Term Single-Center Experience
Q38319989Who and how to screen for cancer in at-risk inflammatory bowel disease patients
Q26746994Worldwide Incidence of Colorectal Cancer, Leukemia, and Lymphoma in Inflammatory Bowel Disease: An Updated Systematic Review and Meta-Analysis

Search more.